top of page

Over 85% of dry eye, tear and eyelid problems originate from meibomian gland dysfunction (MGD) within the eyelid.



The future in eyelid treatment. 

Low Level Light Therapy (LLLT):

The benefits our patients receive from LLLT is simply, unmatched. They are complemented by LLLT exceptional efficacy in treating Meibomian Gland Dysfunction or MGD—although global thought leaders in the scientific community have leveraged it beyond MGD to treat the ocular surface (e.g., Dry Eyes, Chalazia, Styes, Blepharitis, Demodex, Sjögren’s Syndrome).


Low-level Light Therapy is a unique, light-based photobiomodulation technology. It's been developed and patented for medical use with the technology originally employed by NASA (i.e., Low-level Laser Therapy) to treat wounds of astronauts in space.  LLLT has nothing to do with Red Light Therapy (RLT), which only acts on the surface of the dermis.  Instead, Drs. Smarch & Schnurer utilize an LLLT that works at biological level, generating endogenous heat through powerful LEDs stimulating ATP production in cells.

This patented photobiomodulation technology isn’t just like any other red light therapy. It's patented and certified for medical use, designed to leverage near-infrared light beams that solicit cells’ mitochondria, triggering biochemical and biophysical reactions that stimulate them to provide better protein synthesis. Thanks to this process of endogenous heating, the tear lipid layer is increased and stabilized allowing you to feel and see the difference.


LLLT highlights: 

LLLT is used for Inflammation reduction and ATP Production Stimulus.  

- Improves cells metabolism due to increased ATP production within the mitochondria.

- Reduces inflammation by regulating anti-oxidant defenses and reducing oxidative stress.

- Light-induced activation of transcription factors and signaling pathways.

- When a 15-minute treatment is applied, the total fluence in the treated area is 100 Joules/cm2.

bottom of page